Tous Actualités
Suivre
Abonner European Society for Medical Oncology (ESMO)

European Society for Medical Oncology (ESMO)

ESMO Conference 5-8 July 2007, Lugano, Switzerland - Press Program

Lugano (ots)

PLEASE NOTE: FULL TEXT OF THE PRESS RELEASES AVAILABLE THROUGH
WWW.ESMO.ORG/PRESSROOM upon registration PLEASE RESPECT INDIVIDUAL
EMBARGO DATES/TIMES FOUND ON FULL PRESS RELEASES
HORMONE INHIBITOR PROMISING FOR HARD-TO-TREAT
PROSTATE CANCER For prostate cancer patients whose tumors have
continued to grow despite medical or surgical castration, a new drug
candidate that inhibits production of male hormones anywhere in the
body is showing promise in early trials. Two poster to be presented
at the ESMO Conference Lugano (ECLU) show the drug results.
ANALYSIS CONFIRMS BENEFITS OF COMBINING TRASTUZUMAB AND
CHEMOTHERAPY IN BREAST CANCER
An analysis of five major breast cancer trials has confirmed that
combination treatment with the antibody treatment trastuzumab and
chemotherapy improves survival in women with operable HER-2 positive
breast cancer, researchers announce at the ESMO Conference Lugano
(ECLU).
CANCER-FIGHTING VIRUS SHOWS PROMISE IN EARLY TRIAL
A virus that has been specifically designed by scientists to be
safe to normal tissue but deadly to cancer is showing early promise
in a preliminary study. Results from an ongoing trial in patients
with colorectal cancer to be presented at the ESMO Conference Lugano
(ECLU).
AN OPPORTUNITY FOR PATIENTS TO LEARN AND TALK ABOUT CANCER
People affected by cancer in Switzerland and northern Italy have
an opportunity during the ESMO Congress Lugano (ECLU) to talk about
the latest in cancer research and share their knowledge and personal
experiences, at the 6th ESMO Patient Seminar. An important theme of
the seminar is open communication. "Communication is one of the best
weapons we have against cancer," said Prof. Michele Ghielmini, the
chair of the ESMO Patient Seminar Task Force. "That means
communication between doctor and patient, communication between
patients and their families and between patients themselves," he
said.
ESMO RECOGNIZES THE NETHERLANDS CANCER INSTITUTE FOR OUTSTANDING
ACHIEVEMENT IN TRANSLATIONAL RESEARCH IN BREAST CANCER
The European Society for Medical Oncology (ESMO) is pleased to
announce that the Netherlands Cancer Institute (NKI) is the winner of
the second edition of the ESMO Lifetime Achievement Award supported
by an unrestricted grant from GlaxoSmithKline (GSK).
The research group was conferred the award for its outstanding
achievements in the area of Translational Research in Breast Cancer.
The head of the Molecular Carcinogenesis Division of the Institute,
Dr. René Bernards, and the Head of the Molecular Pathology Division,
Dr. Laura van 't Veer, will receive the award on behalf of the
institute during the Opening Ceremony of the ESMO Conference in
Lugano (ECLU) on Thursday, 5 July 2007.
CANCER ON THE AGENDA OF THE PORTUGUESE EU COUNCIL PRESIDENCY ESMO
A MAJOR PLAYER IN THE ROUND TABLE ON HEALTH STRATEGIES IN THE
EUROPEAN UNION
The European Society for Medical Oncology (ESMO) is proud to
announce that it is collaborating closely with the Portuguese EU
Presidency on a key European meeting on health care issues, where
cancer will be an important part of the agenda.
The 'Round Table on Health Strategies in the European Union'
(Lisbon, 12-13 July 2007) is one of numerous initiatives launched by
the EU Portuguese Presidency within the context of the EU strategy on
health policy, focusing on the topic of health and migration. ESMO
has been invited by Dr. Joaquim Gouveia, National Coordinator of
Oncological Diseases in Portugal, to be a key partner in this meeting
for aspects related to cancer.

Contact:

Vanessa Pavinato
European Society for Medical Oncology
Office Phone: +41/91/973'19'07
E-Mail: media@esmo.org